Get the Stockscreener App
14.36
3.17%
-0.47
After Hours:
14.36
Rapport Therapeutics Inc stock is traded at $14.36, with a volume of 115.22K.
It is down -3.17% in the last 24 hours and up +26.30% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$14.83
Open:
$14.62
24h Volume:
115.22K
Relative Volume:
0.66
Market Cap:
$524.11M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.60%
1M Performance:
+26.30%
6M Performance:
-12.49%
1Y Performance:
-36.80%
1-Day Range:
$14.16
$15.75
1-Week Range:
$14.16
$17.45
52-Week Range:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
14.36 | 541.26M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
How to read the order book for Rapport Therapeutics Inc.Intraday Signal Forecast for Fast Traders - Newser
How Rapport Therapeutics Inc. stock performs during market volatilityTechnical Setup Guide for Daily Watchlist - Newser
Rapport Therapeutics Inc. Recovery Hinges on Volume BreakoutAI Screening for Swing Trade Picks Finds Momentum - metal.it
Applying chart zones and confluence areas to Rapport Therapeutics Inc.Weekly Chart Watchlist with Trade Guidance - Newser
Bollinger Bands Show Potential Breakout in Rapport Therapeutics Inc.Short Window Trade Insight Forecast - beatles.ru
Can Rapport Therapeutics Inc. Regain Momentum After BreakdownAI Forecast for Trending Stocks Indicates Upside - metal.it
Volume Surge May Signal Institutional Interest in Rapport Therapeutics Inc.Pattern Detection for Entry Confirmation Enabled - metal.it
Why Ferrovial SE stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
Rapport Therapeutics Inc. Could See a Relief Rally From SupportWatchlist for Smart Swing Trading Updated - metal.it
Is Rapport Therapeutics Inc. stock overvalued or undervaluedInvest confidently with proven investment plans - jammulinksnews.com
How Efficient Is Rapport Therapeutics Inc. at Controlling Operating CostsTrend Following Trades - metal.it
Should I hold or sell Rapport Therapeutics Inc. stock in 2025High-velocity capital appreciation - jammulinksnews.com
What are the technical indicators suggesting about Rapport Therapeutics Inc.Superior profit margins - jammulinksnews.com
Is it the right time to buy Rapport Therapeutics Inc. stockSkyrocketing profit margins - jammulinksnews.com
What is the risk reward ratio of investing in Rapport Therapeutics Inc. stockCapitalize on market momentum for profits - jammulinksnews.com
How strong is Rapport Therapeutics Inc. company’s balance sheetCapitalize on market trends early - jammulinksnews.com
What makes Rapport Therapeutics Inc. stock price move sharplyFree Wealth Planning Blueprint - jammulinksnews.com
What are Rapport Therapeutics Inc. company’s key revenue driversMarket-beating returns - jammulinksnews.com
What is Rapport Therapeutics Inc. company’s growth strategyStay ahead with daily expert stock picks - jammulinksnews.com
Is Rapport Therapeutics Inc. a growth stock or a value stockMarket-crushing profits - jammulinksnews.com
Is Rapport Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideLow Volatility High Yield Stocks - Newser
Why Rapport Therapeutics Inc. stock attracts strong analyst attention5x Profit Potential - Newser
How TRGP stock performs during market volatilityInvestor Favorite Picks - Newser
What analysts say about Rapport Therapeutics Inc. stockDynamic profit opportunities - Autocar Professional
When is the best time to buy Rapport Therapeutics Inc. stockOutstanding yields - jammulinksnews.com
What drives Rapport Therapeutics Inc. stock priceOutstanding stock performance - PrintWeekIndia
How Rapport Therapeutics Inc. stock reacts to Fed policy changesMarket-leading capital gains - jammulinksnews.com
Is Rapport Therapeutics Inc. a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
Rapport Therapeutics Inc. Stock Analysis and ForecastMarket-crushing stock picks - Autocar Professional
How the (RAPP) price action is used to our Advantage - news.stocktradersdaily.com
What drives EOSEW stock priceExceptional gains - Jammu Links News
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):